Viewing nowCombinationAvaltan Tablet 5/160 mg
Valsartan 160mg · Amlodipine Besylate 6.94mg
Tablet · Prescription medication · Combination
Dongu Bio Pharmaceutical Co., Ltd.

MFDS item code 201402897 · Approved 2014.06.30 · Insurance code 657306480
Treatment of essential hypertension not controlled with monotherapy
This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or valsartan alone. The two components work together to effectively lower blood pressure and improve hypertension.
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the dose be adjusted using the individual components (amlodipine or valsartan) before starting this medicine; however, a direct switch to this medicine may be considered if blood pressure is not adequately controlled with monotherapy using the individual components, as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a fixed-dose combination with the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater); however, this medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer this medicine to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose.
Under 18 years: Use of this medicine is not recommended because its safety and efficacy have not been established in pediatric patients.
This medication can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Patients with an allergy to the active ingredients or similar components, women who are pregnant or may become pregnant, nursing mothers, or individuals with severe kidney or liver disease should not take this medication. Patients with sodium or fluid depletion may experience hypotension; therefore, their condition should be stabilized prior to use, and blood pressure should be closely monitored after initiation. Patients with elevated potassium levels should be cautious when taking this medication with other drugs that can increase potassium, and regular checks of blood potassium levels are necessary. Patients with renal artery issues or those who have recently undergone kidney transplants should carefully monitor kidney function while taking this medication. If symptoms of angioedema occur, this medication should be discontinued immediately and should not be restarted thereafter. Patients with heart failure or those recovering from myocardial infarction should closely monitor changes in renal function while taking this medication, and special caution is necessary for patients with acute myocardial infarction. Patients with heart valve diseases such as aortic stenosis or mitral stenosis should also use this medication with special care. Combination with other RAAS (Renin-Angiotensin-Aldosterone System) acting medications is not recommended; if combined, blood pressure, kidney function, and electrolyte levels should be closely monitored. Dizziness or fatigue may occur during driving or operating machinery, necessitating caution. In cases of overdose, hypotension, increased heart rate, and severe cases may result in shock; immediate medical treatment is required. This medication is not recommended for children, as safety and efficacy have not been adequately established. For elderly patients, the same dosage as for adults may be administered, but careful observation is necessary. It is advisable to have regular liver and kidney function tests during the course of this medication, and to consult medical staff immediately if any abnormal symptoms occur.
nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, dizziness, drowsiness, positional dizziness, paresthesia, vertigo, tinnitus, tachycardia, palpitations, syncope, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, dry mouth, rash, erythema, hyperhidrosis, itching, joint swelling, low back pain, arthritis, muscle spasm, lethargy, polyuria, nocturia, erectile dysfunction, edema, localized edema, facial edema, peripheral edema, fatigue, flushing, weakness, facial flushing, decreased hemoglobin, decreased hematocrit, neutropenia, thrombocytopenia, hypersensitivity including serum sickness, increased serum potassium, vasculitis, elevated liver function tests, angioedema, vesicular dermatitis, myalgia, renal failure, kidney damage, elevated serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory infection, viral infection, intestinal vascular edema, diplopia, thrombocytopenia, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremor, sensory decrease, taste disturbance, peripheral neuropathy, hypertonia, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, myocardial infarction, dyspnea, rhinitis, vomiting, dyspepsia, pancreatitis, gastritis, gum hyperplasia, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity, urticaria, erythema multiforme, Stevens-Johnson syndrome, myalgia, urination disorder, nocturnal enuresis, gynecomastia, pain, malaise, chest pain, weight loss, weight gain, elevated liver enzymes, chest discomfort, abdominal discomfort, gastroesophageal reflux disease, neck pain, hypercholesterolemia, hypoglycemia, neuroexcitation, Stevens-Johnson syndrome, chest pain, weight gain, arthralgia, skeletal pain, rhabdomyolysis, gum polymorphism, gastritis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is best to maintain the storage temperature between 1 to 30 degrees Celsius. This helps to preserve the medication's effectiveness and ensures safe use.
Dark yellow rectangular film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationValsartan 160mg · Amlodipine Besylate 6.94mg
Tablet · Prescription medication · Combination
Dongu Bio Pharmaceutical Co., Ltd.
CombinationValsartan 160mg · Amlodipine Besylate 6.94mg
Tablet · Prescription medication · Combination
Novartis Korea Co., Ltd.
CombinationValsartan 80mg · Amlodipine Besylate 6.94mg
Tablet · Prescription medication · Combination
Korea Novartis Co., Ltd.
CombinationValsartan 160mg · Amlodipine Besylate 13.87mg
Tablet · Prescription medication · Combination
Novartis Korea Co., Ltd.
Valsartan · Amlodipine Besylate
Prescription medication · Combination
Korea Sandose Co., Ltd.
Valsartan · Amlodipine Besylate
Prescription medication · Combination
Korea Sandos Co., Ltd.
Valsartan · Amlodipine Besylate
Prescription medication · Combination
Korea Sandos Co., Ltd.
CombinationValsartan 160mg · Amlodipine Besylate 13.87mg
Tablet · Prescription medication · Combination
Myungmoon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.